PROTHENA BIOSCIENCES LIMITED

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
C07K PEPTIDES 30106
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 25230
 
  
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 11195
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 4163
 
  
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 297
 
  
 
A01K ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS147
 
  
 
A61B DIAGNOSIS; SURGERY; IDENTIFICATION 1239
 
  
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 1124

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2017/0204,173 Antibodies to Alpha SynucleinMar 22, 17Jul 20, 17[G01N, C07K]
2017/0192,017 Methods For Detecting Phosphorylated Alpha-SynucleinAug 25, 16Jul 06, 17[G01N, C07K]
2017/0158,755 ANTI-LAMININ4 ANTIBODIES SPECIFIC FOR LG1-3Mar 12, 15Jun 08, 17[C07K]
2017/0129,954 Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus ArteritisSep 16, 16May 11, 17[A61K, C07K]
2017/0101,470 Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus ArteritisSep 16, 16Apr 13, 17[A61K, C07K]
2017/0015,737 ANTI-TRANSTHYRETIN ANTIBODIESJul 02, 16Jan 19, 17[A61K, G01N, C07K]
2017/0002,077 COMBINATION TREATMENT FOR MULTIPLE SCLEROSISMar 12, 15Jan 05, 17[C07K]
2015/0259,419 Anti-MCAM Antibodies and Associated Methods of UseMar 12, 15Sep 17, 15[C12N, G01N, C07K]
2015/0110,777 ANTIBODIES THAT RECOGNIZE IAPPJul 11, 14Apr 23, 15[C07K]
2014/0314,744 MCAM ANTAGONISTS AND METHODS OF TREATMENTJun 06, 12Oct 23, 14[C07K]

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9884906 Humanized antibodies that recognize alpha-synucleinDec 21, 16Feb 06, 18[A61K, G01N, C07K]
9879071 Antibodies to alpha synucleinSep 05, 12Jan 30, 18[A61K, C12Q, C12N, A01K, G01N, C07K]
9879080 Anti-transthyretin antibodiesJul 02, 16Jan 30, 18[A61K, G01N, C07K]
9850302 Antibodies that recognize IAPPJul 11, 14Dec 26, 17[A61K, C07K]
9670273 Humanized antibodies that recognize alpha-synucleinNov 10, 15Jun 06, 17[A61K, C07K]
9605056 Antibodies recognizing alpha-synucleinOct 08, 13Mar 28, 17[A61K, G01N, C07K]
9556259 Humanized antibodies that recognize alpha-synucleinJan 15, 14Jan 31, 17[A61K, C07K]
9447190 Anti-MCAM antibodies and associated methods of useSep 09, 13Sep 20, 16[A61K, C07K]
9234031 Humanized antibodies that recognize alpha-synucleinJul 24, 14Jan 12, 16[A61K, C07K]
9217030 Humanized antibodies that recognize alpha-synucleinJul 24, 14Dec 22, 15[A61K, C07K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2016/0257,736 ANTI-TRANSTHYRETIN ANTIBODIESAbandonedJan 28, 16Sep 08, 16[C07K]
2016/0257,737 ANTI-TRANSTHYRETIN ANTIBODIESAbandonedJan 28, 16Sep 08, 16[C07K]
2016/0251,417 ANTIBODIES RECOGNIZING MEDINAbandonedJan 22, 16Sep 01, 16[A61K, C07K]
2016/0251,418 ANTI-TRANSTHYRETIN ANTIBODIESAbandonedJan 28, 16Sep 01, 16[C07K]
2015/0259,404 ANTIBODIES RECOGNIZING ALPHA-SYNUCLEINAbandonedOct 08, 13Sep 17, 15[A61K, C07K]
2015/0239,980 ANTI-MCAM ANTIBODIES AND ASSOCIATED METHODS OF USEAbandonedSep 09, 13Aug 27, 15[C07K]
2015/0191,541 ANTIBODIES THAT RECOGNIZE IAPPAbandonedDec 05, 14Jul 09, 15[G01N, C07K]
2014/0186,371 COMPOSITIONS AND METHODS FOR TREATING DISEASES OF PROTEIN AGGREGATION INVOLVING IC3B DEPOSITIONAbandonedApr 06, 12Jul 03, 14[A61K, G01N, C07K]

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.